Objective: To evaluate the safety and short-term outcomes of domestic tirofiban in patients with non-ST elevation acute coronary syndrome (NSTEACS) undergoing percutaneous coronary intervention (PCI). Methods:Two hundred and forty-seven patients with NSTEACS were enrolled in the study and divided into two groups: the tirofiban group(n=125) and the control group (n=122). In addition to low molecular weight heparin, patients in the tirofiban group received a dose of tirofiban 0.1 μg/(kg·min) infusion for up to 24 hours after PCI. TIMI grade, platelet aggregation rate and bleeding rate in both groups were investigated and compared before and after PCI. Major adverse cardiac events were also recorded in hospital and during 3 months’ follow-up. Results: Ninty-six percent of patients in the tirofiban group compared with 86.9% in the control group obtained TIMI grade 3 flow(P < 0.05). Platelet aggregation rate in both groups were decreased, and it was lower in the tirofiban group(P < 0.01). There were no serious bleeding complications and MACE in-hospital and follow-up period. Conclusion:Domestic tirofiban is effective on improvement of TIMI grade and prognosis of patients with NSTEACS after PCI.